JPMA Reports Overseas Drug Makers Favoring China Over Japan As R&D Base
This article was originally published in PharmAsia News
Executive Summary
A Japan Pharmaceutical Manufacturers Association policy report shows that U.S. and European drug makers prefer China over Japan in establishing research and development bases. The reasons cited by the JPMA report include China's national policy to promote science and technology and its active recruitment of talent and enterprises from overseas. Additionally, China fosters clusters of domestic and foreign researchers and has improved the environment for R&D, such as the Shanghai Zhangjiang Hi-tech Park, where 120 venture companies, CROs and Shanghai Institute of Material Medica are based. The report also criticized Japan's late response to internationalization in R&D. (Click here for more - Japanese language
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.